Undisclosed TREM-2 inhibitor / SignaBlok - LARVOL DELTA

SignaBlok has received Orphan Drug Designation from the FDA for TREM-1 inhibitor, its investigative therapeutic for the treatment of retinopathy of prematurity (ROP) (Eyes On Eyecare) - "SignaBlok plans to present its first batch of preclinical efficacy pharmacokinetic and tolerability data at the upcoming 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting (May 3-7) in Denver, Colorado...The company noted that the inhibitor—which it described as a 'non-toxic and well-tolerable ligand-independent TREM-1 inhibitor'—was found to significantly reduce (up to 95% retinal neovascularization in the retinas of MICE with OIR."

Orphan drug • Retinopathy of Prematurity